Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2000

View Archived Issues

Cambridge Antibody Technology reports recent developments

Despite positive phase II results, Medivir must seek new partner for ME-609

Herceptin enters phase III trial as adjuvant therapy in early-stage breast cancer

Health Canada clears Enbrel for moderately to severely active RA

FDA approves second indication for Antizol

FDA clearance allows Amarin to begin Huntington's disease trials

Plan B emergency contraceptive now available in Canada

Tamiflu approved in Japan

Altered peptide ligand agreement between Neurocrine Biosciences and Taisho expanded

Berlex now marketing Levulan Kerastick photodynamic therapy in U.S.

Bronchial effects of prostanoid DP antagonist reported at Japanese Society of Allergology meeting

Kaken presents dual LTD4 and TxA2 antagonist with promising antiasthmatic profile

In vitro and in vivo characterization of the newly synthesized thrombin inhibitor AT-1362

Merck & Co. obtains rights to Probiodrug's DP-IV inhibitors for diabetes

AstraZeneca's rosuvastatin will be sold as Crestor

CeNeS shareholders approve acquisition of Cambridge NeuroScience

New agent for atopic dermatitis is endowed with antihistaminic and antiinflammatory effects

Quinoxalinecarboxylic acid-based AMPA receptor antagonists with good solubility characteristics

SmithKline Beecham terminates lotrafiban clinical development

AHP and Ligand collaboration focuses on progesterone receptor modulators

Aza compounds synthesized at Georgetown U. inhibit monoamine neurotransmitter reuptake

Cardiovascular agents useful for hypertension and ischemic disorders discovered at CSIR

Recent Japanese patent reveals new TNF-alpha inhibitors from Snow Brand

Pola's new ACAT inhibitors described in patent literature

Taisho discovers new histamine H2 antagonist with antisecretory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...